Expert Opinion on Biological Therapy

Papers
(The TQCC of Expert Opinion on Biological Therapy is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’?83
Mesothelin-targeted CAR-T cell therapy for solid tumors72
Core decompression isolated or combined with bone marrow-derived cell therapies for femoral head osteonecrosis54
An overview of process development for antibody-drug conjugates produced by chemical conjugation technology48
Therapeutic monoclonal antibodies for COVID-19 management: an update45
New frontiers in personalized medicine in psoriasis44
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma43
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study40
Targeting the complement system in neuromyelitis optica spectrum disorder40
Treating psoriasis in the elderly: biologics and small molecules34
Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions33
A comprehensive review on sarilumab in COVID-1932
Anti-CD20 treatment for B-cell malignancies: current status and future directions31
Hemophilia A gene therapy: current and next-generation approaches30
What makes a good antibody–drug conjugate?29
Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan29
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics29
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis28
Immune checkpoint inhibition in COVID-19: risks and benefits27
The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database27
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy27
Margetuximab for the treatment of HER2-positive metastatic breast cancer26
Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?26
Anticalin® proteins: from bench to bedside25
Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy – what are we doing; where are we going?25
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-1925
Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy24
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma24
Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus24
The effect of platelet-rich plasma-fibrin glue dressing in combination with oral vitamin E and C for treatment of non-healing diabetic foot ulcers: a randomized, double-blind, parallel-group, clinical24
Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders24
A health economic guide to market access of biosimilars24
Rotavirus vaccines: progress and new developments23
B7-H3 targeted antibody-based immunotherapy of malignant diseases23
Isatuximab for the treatment of relapsed/refractory multiple myeloma23
The evolution of bispecific antibodies21
RNA therapeutics for retinal diseases21
Therapeutic potential of biologics in prurigo nodularis20
Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma20
AIRMESS – Academy of International Regenerative Medicine & Surgery Societies: recommendations in the use of platelet-rich plasma (PRP), autologous stem cell-based therapy (ASC-BT) in androgenetic 20
Prostate cancer immunotherapy20
Enfortumab vedotin – next game-changer in urothelial cancer20
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy20
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy19
Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis18
HIV-1 cure strategies: why CRISPR?18
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond18
Onasemnogene abeparvovec for the treatment of spinal muscular atrophy18
Brolucizumab: a novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD16
Ranibizumab for the treatment of diabetic retinopathy16
Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer16
Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?15
An inflammatory triangle in Sarcoidosis: PPAR-γ, immune microenvironment, and inflammation15
Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice15
Injectable and adhesive hydrogels for dealing with wounds14
Immune checkpoint inhibitors for the treatment of melanoma14
Survivin as a biological biomarker for diagnosis and therapy14
Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome14
Targeting glyco-immune checkpoints for cancer therapy14
CRISPR/Cas9 gene editing therapies for cystic fibrosis13
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phas13
A Randomized Controlled Ixekizumab Vs Secukinumab Trial to Study the Impact on Sexual Activity in Adult Patients with Genital Psoriasis13
Conventional type 1 dendritic cells (cDC1) as cancer therapeutics: challenges and opportunities13
The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?13
The emerging role of dupilumab in dermatological indications13
Biologics in food allergy: up-to-date13
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations12
Potential applications of mesenchymal stem cells and their derived exosomes in regenerative medicine12
Self-administration of omalizumab: why not? A literature review and expert opinion12
A review of imlifidase in solid organ transplantation12
Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy12
Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma12
Mechanism of Action of Mesenchymal Stem Cells (MSCs): impact of delivery method12
Next steps for the optimization of exon therapy for Duchenne muscular dystrophy12
Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis12
Luspatercept for β-thalassemia: beyond red blood cell transfusions12
Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy11
Bispecific antibodies for the treatment of breast cancer11
Gene Therapy for High Grade Glioma: The Clinical Experience11
Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience11
Anti-IL 23 biologics for the treatment of plaque psoriasis11
Bio-nano scale modifications of melittin for improving therapeutic efficacy11
Belimumab: a step forward in the treatment of systemic lupus erythematosus11
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives11
Emerging treatment landscape of non-muscle invasive bladder cancer10
Immunomodulatory extracellular vesicles: an alternative to cell therapy for COVID-1910
Envafolimab – first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors10
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study10
Role of extracellular vesicles in severe pneumonia and sepsis10
Oncolytic virus therapy for malignant gliomas: entering the new era10
Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk10
The manufacturing considerations of bispecific antibodies9
Nivolumab for the treatment of esophageal cancer9
Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus9
Classification and coding systems for platelet-rich plasma (PRP): a peek into the history9
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents9
Sargramostim in acute radiation syndrome9
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks9
Gene therapy for alpha-1 antitrypsin deficiency: an update9
Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer9
IL-23 inhibition for the treatment of psoriatic arthritis9
Platelet-rich plasma therapy ensures pain reduction in the management of lateral epicondylitis – a PRISMA-compliant network meta-analysis of randomized controlled trials9
Harmonizing PD-L1 testing in metastatic triple negative breast cancer9
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors9
Evaluation of canine bone marrow-derived mesenchymal stem cells for experimental full-thickness cutaneous wounds in a diabetic rat model9
Alternative therapeutic strategy for existing aortic aneurysms using mesenchymal stem cell–derived exosomes9
Paradoxical reactions to biologicals for psoriasis9
Bispecific CAR T-cells for B-cell Malignancies9
Total pancreatectomy with intraportal islet autotransplantation for pancreatic malignancies: a literature overview9
Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry9
Emerging therapies for human hearing loss8
Biological and genetic therapies for the treatment of Duchenne muscular dystrophy8
Current developments in gene therapy for epidermolysis bullosa8
Tocilizumab for the treatment of COVID-198
Biological agents targeting interleukin-13 for atopic dermatitis8
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks8
IBD goes home: from telemedicine to self-administered advanced therapies8
Current and Future Options of Haemophilia A Treatments8
Cell-based therapy in soft tissue sports injuries of the knee: a systematic review8
Cell therapy for cytomegalovirus infection8
Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation8
A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence8
Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing8
Biosimilars: A futuristic fast-to-market advice to developers8
The Role of Anti-IL-1 Treatment in MIS-C Patients8
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease8
How can clinical safety and efficacy concerns in stem cell therapy for spinal cord injury be overcome?8
Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi TM ): a multidisciplinary perspective8
Current status of developing tissue engineering vascular technologies8
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study8
Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques8
Biologic treatment of psoriasis in oncologic patients8
The global landscape on interchangeability of biosimilars8
0.053412914276123